Protalix BioTherapeutics financials
$2.690.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19.9M | $33.8M | $9.1M | $17.9M | $15.7M | $10.1M | $18.2M | $18.0M | $13.5M | $3.7M | $10.5M | $10.3M |
| Gross profit | $12.1M | $29.6M | $4.5M | $9.5M | $9.8M | $1.9M | $14.3M | $9.6M | $4.0M | $1.1M | $1.6M | $5.5M |
| Gross margin | 61.0% | 87.8% | 49.4% | 53.4% | 62.5% | 19.1% | 78.7% | 53.4% | 29.8% | 30.6% | 15.5% | 52.7% |
| Operating income | $4.7M | $21.1M | -$4.7M | $2.1M | $1.2M | -$4.1M | $7.2M | $4.0M | -$2.4M | -$4.9M | -$5.6M | -$1.9M |
| Net income | $3.8M | $18.3M | -$5.5M | $2.4M | $164.0K | -$3.6M | $6.5M | $3.2M | -$2.2M | -$4.6M | -$6.0M | -$1.9M |
| Net margin | 19.0% | 54.3% | −60.3% | 13.2% | 1.0% | −35.8% | 35.6% | 18.0% | −16.4% | −122.6% | −57.6% | −17.9% |
| Diluted EPS | $0.05 | $0.22 | $-0.07 | $0.03 | $0.00 | $-0.05 | $0.07 | $0.03 | $-0.03 | $-0.06 | $-0.06 | $-0.04 |
| EBITDA | $5.1M | $21.6M | -$4.3M | $2.5M | $1.5M | -$3.8M | $7.5M | $4.3M | -$2.1M | -$4.5M | -$5.3M | -$1.6M |
| Operating cash flow | -$10.4M | $22.0M | $2.0M | -$3.7M | -$5.2M | -$5.1M | $4.0M | $4.1M | -$3.6M | $4.2M | $3.6M | -$6.9M |
| Free cash flow | -$11.0M | $21.3M | $1.6M | -$4.2M | -$5.7M | -$5.4M | $3.6M | $4.0M | -$3.8M | $3.6M | $3.3M | -$7.3M |
| Diluted shares | 82.6M | 83.0M | 75.5M | 80.8M | 81.3M | 76.6M | 96.7M | 81.2M | 73.3M | 73.0M | 105.2M | 83.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $27.4M | $41.0M | $14.7M | $13.6M | $17.9M | $19.5M |
| Short-term investments | $13.2M | $10.1M | $15.6M | $15.7M | $15.5M | $15.3M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $110.3M | $102.3M | $82.3M | $82.3M | $78.5M | $73.9M |
| Total liabilities | $38.9M | $35.1M | $34.1M | $29.4M | $28.6M | $28.7M |
| Shareholders' equity | $71.4M | $67.2M | $48.2M | $52.9M | $49.9M | $45.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology